Detalhe da pesquisa
1.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(23): 2197-2206, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469184
2.
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
J Urol
; 209(3): 532-539, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36756959
3.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Future Oncol
; 19(29): 1953-1960, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37585665
4.
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Future Oncol
; 18(35): 3867-3874, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226865
5.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV201): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 872-882, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991512
6.
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Breast Cancer Res Treat
; 187(1): 155-165, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33591468
7.
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Gynecol Oncol
; 149(2): 275-282, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29454514
8.
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 171-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25547219
9.
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
Eur Urol
; 81(5): 515-522, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35168844
10.
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
Clin Drug Investig
; 41(9): 795-808, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34351608
11.
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
Eur J Cancer
; 159: 237-246, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34784577
12.
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Eur Urol
; 78(6): 847-853, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010985
13.
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
JAMA Oncol
; 6(2): 217-225, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31830211
14.
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.
Clin Cancer Res
; 26(23): 6149-6157, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988969
15.
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
J Clin Oncol
; 36(9): 884-890, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29373071
16.
Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
Clin Drug Investig
; 42(3): 283, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220556
17.
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.
Clin Cancer Res
; 23(15): 4046-4054, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28280092
18.
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Clin Lung Cancer
; 18(1): 34-42.e2, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27686971
19.
A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
Leuk Lymphoma
; 57(8): 1848-55, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26857688
20.
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
Clin Cancer Res
; 10(21): 7244-51, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15534098